Navigation Links
US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
Date:6/2/2008

d

hyperlipidemia in patients with advanced renal cell carcinoma

treated with temsirolimus or interferon

Gynecologic

-- Michael Teneriello, M.D., Texas Oncology-Austin Central, co-chair,

US Oncology Gynecologic Cancer Research Committee: Phase III trial of

induction gemcitabine (G) or paclitaxel (T) plus carboplatin (C)

followed by elective T consolidation in advanced ovarian cancer (OC):

Interim analysis of induction chemotherapy

Melanoma

-- William Stephenson, M.D., Kansas City Cancer Center-South: PhaseI/II

study of imexon (AMP) plus dacarbazine (DTIC) in patients (Pts) with

metastatic malignant melanoma

Leukemia

-- Roger Lyons, M.D., Cancer Care Centers of South Texas-Medical Center:

Phase II study of single agent clofarabine in previously untreated

older adult patients with acute myelogenous leukemia (AML) unlikely to

benefit from standard induction chemotherapy

Solid Tumors

-- William Stephenson, M.D., Kansas City Cancer Center-South: Phase I

study multicenter study to assess the safety, tolerability, and

pharmacokinetics of AZD4877 administered twice weekly in adult

patients with advanced solid malignancies

-- Robert Raju, M.D., Dayton Oncology & Hematology-Kettering: An open

label Phase I dose escalation study of ADH-1 in combination with

chemotherapy in subjects with N-Cadherin expressing solid tumors

Lymphoma and Plasma Cell Disorders

-- Alan Feiner, M.D., Rocky Mountain Cancer Centers-Rose, and John

Mattern, D.O., Virginia Oncology Associates-Newport News: Primary

therapy of Waldenstrom's macroglobulinemia with bortezomib,

dexamethasone and rituximab: results of WMCTG Clinical Trial 05-180

About US Oncology Research

The US Oncology Research network is an established communit
'/>"/>

SOURCE US Oncology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
2. New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
3. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
4. BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
5. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
6. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
7. Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
8. Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
9. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
10. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
11. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014  ResMed (NYSE: ... of the ResMed Data Exchange program, a comprehensive ... medical equipment (HME) and other health care providers. ... secure access to critical patient information. It integrates ... AirView™ and U-Sleep™ patient management platforms with customers, ...
(Date:10/20/2014)...  AnaptysBio, Inc., a leader in the discovery ... appointment of Marco Londei , M.D. as ... preclinical and clinical development of AnaptysBio,s proprietary antibody ... welcome Dr. Londei to AnaptysBio,s executive leadership team," ... Executive Officer of AnaptysBio. "Dr. Londei,s extensive expertise ...
(Date:10/20/2014)... 20, 2014 Pharmaceutic Labs announces the opening ... Albany, NY for admixing, compounding, drug ... and/or exceeds the FDA standards for safety and quality, ... 211. The 10,000 square foot outsourcing ... quality assurance and quality control. The company will produce ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
... N.J., Jan. 6, 2012 Savient Pharmaceuticals, Inc. (NASDAQ: ... code, or permanent J-code, for KRYSTEXXA® (pegloticase) became available ... assigned by the Centers for Medicare and Medicaid Services ... process for prescribers of KRYSTEXXA, the first and only ...
... 6, 2012 Biodel Inc. (Nasdaq: BIOD ) ... of Biodel, will present a corporate update at the 30th ... 1:00 p.m. Pacific Time (4:00 p.m. Eastern Time). ... 2012, at the Westin St. Francis Hotel in San Francisco, ...
Cached Medicine Technology:Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA® 2Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA® 3Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA® 4Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA® 5Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA® 6
(Date:10/20/2014)... T.E.N., a technology and information security ... William H. Murray, renowned author and industry visionary, ... Award winner. Presented annually, the ISE® Luminary Leadership ... and industry practitioner for his or her distinguished ... security industry. , Formerly with IBM, Murray is ...
(Date:10/20/2014)... Principle Business Enterprises, a family owned company ... absorbent products. The company has recently made efforts ... Tranquility® Premium Protection absorbent products. The company has ... packaging a new look, and is currently working on ... public. , The new website, developed with Thread Marketing ...
(Date:10/20/2014)... 20, 2014 Based on a ... only imaging assays capable of determining DNA sequence, ... With these three dimensions of high-resolution data, dGH ... the widest range of disease-causing genetic rearrangements, including ... other genomic tools, including today’s advanced sequencing technologies. ...
(Date:10/20/2014)... 2014 Punzoné , the first line ... has a lot to celebrate this month. October marks Italian ... achievements and contributions of Americans of Italian heritage and Italians ... today it shares its favorite Italian cocktails and encourages everyone ... - even if it is only in a glass. ...
(Date:10/19/2014)... BambooIndustry.com, one of the most popular suppliers of bamboo ... deckings . Moreover, the company has launched a special ... at deeply discounted rates. , As is known ... significance of online business nowadays. Thus, BambooIndustry.com pays a ... are striving to deliver both value and efficiency for ...
Breaking Medicine News(10 mins):Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2
... 2008) The Virginia Commonwealth University School of Medicine ... from the National Institutes of Healths National Institute on ... syndrome, a disorder of the endocrine system that affects ... syndrome, or PCOS, causes hormonal imbalances leading to irregular ...
... LAKE CITY, May 12 Dynatronics,Corporation (Nasdaq: ... quarter,ended March 31, 2008 on Wednesday, May 14, ... for investors later that,day at 2:30 p.m. ET ... nine month,periods. Those interested in participating should call ...
... to expand oral health care services; awards two significant oral health ... ... As part of the Illinois,Children,s Healthcare Foundation,s (ILCHF) $20 million, five-year,initiative to ... to announce a request for proposals in the oral,health care field. The ...
... http://www.cryocath.com Toronto Stock Exchange Symbol: CYT, MONTREAL, ... in cryotherapy products to treat cardiac,arrhythmias, today announced financial ... Selected Second Quarter Financial and Operational Highlights:, ... to $10.2 million or a 37.6% ...
... MELVILLE, N.Y., May 12 Gentiva Health,Services, Inc. (Nasdaq: ... health services, announced today that it is scheduled to,present ... 21, 2008 at the 2008,Citi Investment Research Global Health ... be available to the public via a live audio ...
... Low IQ more likely the younger a child is at diagnosis, ... about 5 percent of people with multiple sclerosis are diagnosed when ... cognitive function, causing memory and attention problems, and possibly low IQ ... time of diagnosis, the more likely he or she is to ...
Cached Medicine News:Health News:NIH grant to support Translational Research Center for PCOS 2Health News:Children in Illinois to Have Healthier Smiles 2Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 2Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 3Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 4Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 5Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 6Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 7Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 8Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 9Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 10Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 11Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 12Health News:Gentiva(R) Health Services to Present May 21 at 2008 Citi Investment Research Global Health Care Conference in New York 2Health News:Gentiva(R) Health Services to Present May 21 at 2008 Citi Investment Research Global Health Care Conference in New York 3Health News:Multiple Sclerosis Affects Children's Cognitive Skills 2Health News:Multiple Sclerosis Affects Children's Cognitive Skills 3
Schlesinger Laminectomie Rongeur, golden springs. 15 cm - 6, with narrow footplate, large handle, 40 down-cutting, jaws 3 mm wide....
... The Tangent Posterior Impacted Instrument Set offers ... of the advantages offered by the Tangent ... preparation and the ability to reproduce the ... to ensure proper vertebral body distraction. A ...
Codman Hakim Programmable micro with Rickham Reservoir offers the ability to optimize the opening pressure of a shunt system before and after implantation. A shunted patient's condition will often ch...
... Osteopal V is a low viscosity ... use in vertebroplasty. The bone cement is ... stabilization purposes. Osteopal V is used for ... concentration of zirconium dioxide is included in ...
Medicine Products: